151 related articles for article (PubMed ID: 24413373)
21. Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function.
Borin MT; Lo A; Barnes CN; Pendyala S; Bourdet DL
Int J Chron Obstruct Pulmon Dis; 2019; 14():2305-2318. PubMed ID: 31632000
[TBL] [Abstract][Full Text] [Related]
22. A single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairment.
Bramson C; Ouellet D; Roman D; Randinitis E; Gardner MJ
J Clin Pharmacol; 2006 Jan; 46(1):29-36. PubMed ID: 16397281
[TBL] [Abstract][Full Text] [Related]
23. Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
Iwamoto M; Hanley WD; Petry AS; Friedman EJ; Kost JT; Breidinger SA; Lasseter KC; Robson R; Lunde NM; Wenning LA; Stone JA; Wagner JA
Antimicrob Agents Chemother; 2009 May; 53(5):1747-52. PubMed ID: 19223645
[TBL] [Abstract][Full Text] [Related]
24. Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use.
Pinkerton JV; Kagan R
Expert Opin Pharmacother; 2015; 16(17):2703-14. PubMed ID: 26634778
[TBL] [Abstract][Full Text] [Related]
25. Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials.
Simon JA; Altomare C; Cort S; Jiang W; Pinkerton JV
J Womens Health (Larchmt); 2018 Jan; 27(1):14-23. PubMed ID: 29064335
[TBL] [Abstract][Full Text] [Related]
26. Vaginal effects of ospemifene in the ovariectomized rat preclinical model of menopause.
Unkila M; Kari S; Yatkin E; Lammintausta R
J Steroid Biochem Mol Biol; 2013 Nov; 138():107-15. PubMed ID: 23665515
[TBL] [Abstract][Full Text] [Related]
27. The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor.
Eley T; He B; Chang I; Colston E; Child M; Bedford W; Kandoussi H; Pasquinelli C; Marbury TC; Bertz RJ
Antivir Ther; 2015; 20(1):29-37. PubMed ID: 24704773
[TBL] [Abstract][Full Text] [Related]
28. Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study.
Peveling-Oberhag J; Zeuzem S; Yong WP; Kunz T; Paquet T; Bouillaud E; Urva S; Anak O; Sellami D; Kobalava Z
Clin Ther; 2013 Mar; 35(3):215-25. PubMed ID: 23453404
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, in patients with moderate hepatic impairment.
Wang YH; Liu F; Luk JA; Nirula A; Johnson-Levonas AO; Lasseter KC; Marbury TC; Lunde NM; Wagner JA; Lai E
J Clin Pharmacol; 2011 Mar; 51(3):406-12. PubMed ID: 20484612
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and Safety of Momelotinib in Subjects With Hepatic or Renal Impairment.
Xin Y; Kawashima J; Weng W; Kwan E; Tarnowski T; Silverman JA
J Clin Pharmacol; 2018 Apr; 58(4):522-532. PubMed ID: 29283448
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics, pharmacodynamics and clinical efficacy of ospemifene for the treatment of dyspareunia and genitourinary syndrome of menopause.
Bondi C; Ferrero S; Scala C; Tafi E; Racca A; Venturini PL; Leone Roberti Maggiore U
Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1233-46. PubMed ID: 27476551
[TBL] [Abstract][Full Text] [Related]
32. Ospemifene in the treatment of vulvovaginal atrophy.
Barnes KN; Pearce EF; Yancey AM; Forinash AB
Ann Pharmacother; 2014 Jun; 48(6):752-7. PubMed ID: 24615631
[TBL] [Abstract][Full Text] [Related]
33. Pharmacologic evaluation of ospemifene.
McCall JL; DeGregorio MW
Expert Opin Drug Metab Toxicol; 2010 Jun; 6(6):773-9. PubMed ID: 20429673
[TBL] [Abstract][Full Text] [Related]
34. Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib.
Small DS; Zhang W; Royalty J; Cannady EA; Downs D; Ortega D; Suico JG
Eur J Clin Pharmacol; 2016 May; 72(5):563-72. PubMed ID: 26857125
[TBL] [Abstract][Full Text] [Related]
35. Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.
McLendon AN; Clinard VB; Woodis CB
Pharmacotherapy; 2014 Oct; 34(10):1050-60. PubMed ID: 25052122
[TBL] [Abstract][Full Text] [Related]
36. Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant.
Dayal S; Aluri J; Hall N; Filippov G; Moline M; Reyderman L; Landry I
Pharmacol Res Perspect; 2021 Apr; 9(2):e00758. PubMed ID: 33822479
[TBL] [Abstract][Full Text] [Related]
37. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment.
Dowell JA; Stogniew M; Krause D; Damle B
J Clin Pharmacol; 2007 Apr; 47(4):461-70. PubMed ID: 17389555
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic profile of defibrotide in patients with renal impairment.
Tocchetti P; Tudone E; Marier JF; Marbury TC; Zomorodi K; Eller M
Drug Des Devel Ther; 2016; 10():2631-41. PubMed ID: 27574402
[TBL] [Abstract][Full Text] [Related]
39. Effect of Hepatic or Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Ponesimod, a Selective S1P1 Receptor Modulator.
Guérard N; Zwingelstein C; Hoch M; Dingemanse J
Basic Clin Pharmacol Toxicol; 2016 May; 118(5):356-68. PubMed ID: 26525450
[TBL] [Abstract][Full Text] [Related]
40. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.
Bachmann GA; Komi JO;
Menopause; 2010; 17(3):480-6. PubMed ID: 20032798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
